Consolidated EBITDA rose 24% to Rs 78 crore in Q2 September 2019 from Rs 62.8 crore in Q2 September 2018. EBITDA margin contracted to 33% in Q2 September 2019 as against a 39% in Q2 September 2018.
Caplin Point Laboratories is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has a state of the art manufacturing facilities that cater to a complete range of finished dosage forms.
Shares of Caplin Point Laboratories traded 2.94% higher at Rs 397.40.
